Health
Moderna and Merck's mRNA Melanoma Vaccine: What the Phase 3 Results Show
Adding a personalised mRNA vaccine to Keytruda cut the risk of melanoma returning or death by 42 percent in a large phase 3 trial. It is a real advance, but not yet approved, and not the cure early headlines implied.